MMP26: A potential biomarker for prostate cancer

Abstract

The application of prostate-specific antigen (PSA) in the screening and diagnosis of prostate cancer (PCa) has improved the clinical management of PCa patients. However, the PSA assay has been faced with criticism due to its potential association with over-diagnosis and subsequent overtreatment of indolent patients. Matrix metalloproteinase-26 (MMP26) is a member of matrix metalloproteinases (MMPs) and has been reported to be highly expressed in many cancers. This investigation evaluated the potential of serum MMP26 as a biomarker for PCa. The level of serum MMP26 was measured by enzyme-linked immunosorbent assay (ELISA) in 160 subjects including PCa group (n=80), benign prostatic hyperplasia (BPH) group (n=40) and control group (n=40). Furthermore, we evaluated the expression of MMP26 in tissues by immunohistochemistry. The results showed the serum MMP26 levels were significantly higher in PCa group than in BPH group and control group. Similarly, the MMP26 protein was positive in PCa tissues and negative in BPH tissues and control tissues. In conclusion, these results suggested MMP26 could be used as a potential serum biomarker in the diagnosis of PCa.

Keywords

prostate cancer / matrix metalloproteinase-26 / serum biomarker

References

[1] DeSantisCE, LinCC, MariottoAB, et al. . Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin, 2014, 64(4): 252-271 PMID: 24890451

[2] HarveyP, BasuitaA, EndersbyD, et al. . A systematic review of the diagnostic accuracy of prostate specific antigen. BMC Urol, 2009, 9: 14 PMID: 19744336 PMCID: 2753579

[3] CatalonaWJ, PartinAW, SandaMG, et al. . A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol, 2011, 185(5): 1650-1655 PMID: 21419439 PMCID: 3140702

[4] RoddamAW, DuffyMJ, HamdyFC, et al. . Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2–10 ng/mL: systematic review and meta-analysis. Eur Urol, 2005, 48(3): 386-399 PMID: 15982797

[5] CatalonaWJ, RichieJP, AhmannFR, et al. . Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol, 1994, 151(5): 1283-1290 PMID: 7512659

[6] ColeyCM, BarryMJ, FlemingC, et al. . Early detection of prostate cancer. Part I: Prior probability and effectiveness of tests. The American College of Physicians. Ann Intern Med, 1997, 126(5): 394-406 PMID: 9054286

[7] YangCC, SunSS, LinCY, et al. . Differentiation of prostate cancer and benign prostatic hyperplasia: the clinical value of 201Tl SPECT—a pilot study. Ann Nucl Med, 2003, 17(7): 521-524 PMID: 14651349

[8] AmalineiC, CaruntuID, GiuscaSE, et al. . Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol, 2010, 51(2): 215-228 PMID: 20495735

[9] Rita BalistreriC, AllegraA, CrapanzanoF, et al. . Matrix metalloproteinases (MMPs), their genetic variants and miRNA in mitral valve diseases: potential biomarker tools and targets for personalized treatments. J Heart Valve Dis, 2016, 25(4): 463-474 PMID: 28009951

[10] FengYH, WuLS, SuJ, et al. . Expression and significance of MMP-26, TIMP-4 and MMP-9 in diffuse large B-cell lymphoma cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi (Chinese), 2013, 21(5): 1167-1172

[11] MarchenkoGN, RatnikovBI, RozanovDV, et al. . Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem J, 2001, 356(Pt3): 705-718 PMID: 11389678 PMCID: 1221897

[12] IsakaK, NishiH, NakaiH, et al. . Matrix metalloproteinase-26 is expressed in human endometrium but not in endometrial carcinoma. Cancer, 2003, 97(1): 79-89 PMID: 12491508

[13] YangXH, RichardsonAL, Torres-ArzayusMI, et al. . CD151 accelerates breast cancer by regulating alpha 6 integrin function, signaling, and molecular organization. Cancer Res, 2008, 68(9): 3204-3213 PMID: 18451146 PMCID: 4764302

[14] HuQ, YanC, XuC, et al. . Matrilysin-2 expression in colorectal cancer is associated with overall survival of patients. Tumour Biol, 2014, 35(4): 3569-3574 PMID: 24318970

[15] XuX, MaJ, LiC, et al. . Regulation of chondrosarcoma invasion by MMP26. Tumour Biol, 2015, 36(1): 365-369 PMID: 25262277

[16] ZhangY, ZhaoH, WangY, et al. . Non-small cell lung cancer invasion and metastasis promoted by MMP-26. Mol Med Rep, 2011, 4(6): 1201-1209 PMID: 21805034

[17] ZhaoYG, XiaoAZ, NiJ, et al. . Expression of matrix metalloproteinase-26 in multiple human cancer tissues and smooth muscle cells. Ai Zheng, 2009, 28(11): 1168-1175 PMID: 19895737

[18] KhamisZI, IczkowskiKA, ManYG, et al. . Evidence for a proapoptotic role of matrix metalloproteinase-26 in human prostate cancer cells and tissues. J Cancer, 2016, 7(1): 80-87 PMID: 26722363 PMCID: 4679384

[19] CatalonaWJ, SmithDS, RatliffTL, et al. . Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med, 1991, 324(17): 1156-1161 PMID: 1707140

[20] SchroderFH, HugossonJ, RoobolMJ, et al. . Prostate-cancer mortality at 11 years of follow-up. N Engl J Med, 2012, 366(11): 981-990 PMID: 22417251 PMCID: 6027585

[21] Romero OteroJ, Garcia GomezB, Campos JuanateyF, et al. . Prostate cancer biomarkers: an update. Urol Oncol, 2014, 32(3): 252-260 PMID: 24495450

[22] WangT, XieZP, HuangZS, et al. . Total triterpenoids from Ganoderma Lucidum suppresses prostate cancer cell growth by inducing growth arrest and apoptosis. J Huazhong Univ Sci Technol [Med Sci], 2015, 35(5): 736-741